They conducted an open-label, single-injection, dose-escalation, phase I trial with 13 patients with symptomatic refractory gout and a plasma uric acid concentration (pUAc) of >7 mg/dl.

US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

Armed with a pair of phase 3 trial readouts, the two companies are planning to file for approval of their first-in-class candidate SEL-212 for patients with chronic refractory gout next year.

Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.

EULAR 2024 New Gout Drugs Might Increase Patients at Target Urate Level New options in late stages of clinical testing for refractory gout promise to increase the chances of reaching the guideline ...